FDA Import Compliance for Pharmaceutical and Biologics Importers: A Practical Guide

More than 85 percent of the brand-name pharmaceuticals dispensed in the United States are manufactured overseas, and the active pharmaceutical ingredients, biologic drug substances, and finished products that supply the American market cross the border through a single regulatory gate: the U.S. Food and Drug Administration’s import program. Every one of those shipments is electronically screened, risk-scored, and either released or held before it reaches a manufacturing site, a distribution center, or a patient. For the supply chain, quality, and trade-compliance leaders responsible for keeping regulated product moving, the FDA import process is not a customs formality. It is an admissibility decision that can stop a high-value drug substance shipment at the port of entry with no recourse other than export or destruction within 90 days.

The rules that govern that decision are distributed across Section 801 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381), Title 21 of the Code of Federal Regulations, and a set of electronic systems most importers never interact with directly. Understanding how those pieces fit together, who FDA holds accountable, what data must accompany an entry, how shipments are screened, and what happens when a product is flagged, is the difference between a predictable import program and one that absorbs detentions, demurrage charges, and lost batches.

This guide walks through the FDA import compliance framework for pharmaceutical and biologics importers end to end: the establishment registration obligations that precede the first shipment, the electronic entry data that determines screening outcomes, the three dispositions every entry line receives, the import-alert mechanism that can subject a firm’s product to detention without any physical examination, and the operational practices that keep an import program audit-ready.

For an FDA-regulated drug or biologic, admissibility is determined largely by the data submitted before the shipment arrives, not by the quality of the product inside the container. A compliant product accompanied by an incomplete or inaccurate entry is, functionally, a detained product.

The FDA Import Compliance Framework at a Glance

The table below summarizes the principal compliance elements every pharmaceutical or biologics importer must satisfy, the authority that governs each, and the consequence of getting it wrong.

Who Counts as an Importer, and What FDA Holds Accountable

FDA defines the person who imports or offers a drug for import as the owner or exporter who consigns and ships the drug from a foreign country to the United States. This definition is deliberately broad: it captures the entity that controls the goods, not merely the carrier that transports them, and it includes firms that send product by international mail or private delivery service. The practical consequence is that responsibility for admissibility cannot be outsourced to a freight forwarder or a carrier, it follows the owner of the goods.

Every imported shipment of an FDA-regulated product is reviewed against the same standards that apply to domestic product. There is no relaxed standard for imports. A finished drug, an API, or a biologic offered for import must meet the adulteration, misbranding, and approval requirements of the Federal Food, Drug, and Cosmetic Act, and FDA may refuse entry to any article that violates, or merely appears to violate, those requirements. The phrase “appears to violate” is doing significant work: FDA does not need to prove a violation to detain a shipment. The appearance of one, based on the data submitted or the firm’s compliance history, is sufficient.

A product that has never left a temperature-controlled, GMP-validated supply chain can still be refused admission on documentary grounds alone. Admissibility is a function of registration, listing, entry data, and compliance history, not solely product quality.

Foreign Establishment Registration, Drug Listing, and the U.S. Agent

Before a single shipment moves, the foreign establishment that manufactures the drug must satisfy the registration and listing requirements of 21 CFR Part 207. The regulation requires that all manufacturers, repackers, relabelers, and salvagers register each foreign establishment that manufactures, repacks, relabels, or salvages a drug that is imported or offered for import into the United States, and that each drug in commercial distribution be listed with FDA. Drugs regulated under a Biologics License Application fall within the same framework.

The Single U.S. Agent Requirement

Every registrant of a foreign establishment must designate a single United States agent. FDA’s rule is specific about what that agent must be: a person who resides or maintains a place of business in the United States and who is physically present, not a mailbox, an answering machine, or an answering service. The U.S. agent is responsible for reviewing, disseminating, routing, and responding to all FDA communications, including emergency communications, and for answering questions about the drugs being imported. Critically, FDA treats information provided to the U.S. agent as equivalent to information provided to the foreign registrant. The U.S. agent is therefore not an administrative convenience; it is the legal point of contact through which FDA reaches the foreign manufacturer.

If a foreign establishment is required to register under Part 207 but has not, the products it ships are subject to refusal. Establishment registration is a precondition to admissibility, not a parallel paperwork track that can be reconciled after the goods arrive.

The Electronic Entry: How FDA and CBP Share the Border

FDA does not operate its own border-clearance system in isolation. Import entries are filed with U.S. Customs and Border Protection, and FDA-specific data is transmitted electronically through CBP’s Automated Commercial Environment (ACE), the single window through which the two agencies coordinate. Under 21 CFR Part 1 Subpart D, electronic import entries for FDA-regulated products must carry the data elements FDA needs to make an admissibility determination, and a licensed customs broker typically files this information as part of the pre-arrival entry process alongside the entry bond required by CBP.

Affirmation of Compliance Codes and the Drug Registration Number

Among the most consequential data elements are the Affirmation of Compliance (A of C) codes. Some A of C codes are mandatory for a given product; others are voluntary. The submission of correct voluntary codes in addition to all mandatory codes can expedite FDA’s initial screening and significantly increase the likelihood that an entry line receives an automated release. Many A of C codes require a manufacturer’s registration number or a product’s approval number, data that ties the shipment back to a registered establishment and an approved product.

For drugs, the 2016 ACE final rule requires submission, at the time of entry, of the Drug Registration Number, the unique facility identifier of the foreign establishment where the drug was manufactured, prepared, propagated, compounded, or processed before being offered for import, when that establishment is required to register under Part 207 or Part 607. Providing the correct codes reduces the likelihood that a shipment is held for further review.

The single most controllable variable in an import program is the accuracy and completeness of the entry data. Correct Affirmation of Compliance codes and a valid Drug Registration Number are what move an entry line toward an automated “May Proceed” rather than into a manual review queue.

How FDA Screens Every Shipment: PREDICT, ImportShield, and SERIO+

The initial electronic review of every FDA-regulated entry is performed by PREDICT, the Predictive Risk-based Evaluation for Dynamic Import Compliance Targeting system. PREDICT is a risk-based analytics tool that electronically screens all regulated shipments offered for import, using automated data mining, pattern discovery, and queries of FDA databases to assign each shipment a risk score. That score reflects both the inherent risk of the product and the specific history of the importer, manufacturer, and shipper involved. The system is designed to expedite the entry of low-risk, non-violative goods while concentrating human review on shipments that warrant it.

Entries that PREDICT does not clear automatically are routed for human review. In 2025, FDA modernized this function under the FDA ImportShield Program (FISP), supported by the advanced System for Entry Review and Import Operations (SERIO+). ImportShield reviewers assess the information submitted about a shipment to determine admissibility, release or refusal, using PREDICT, SERIO+ Entry Review, and FDA’s internal systems. The modernization is significant for importers because it tightens the link between a firm’s data quality and compliance history and the speed of its border clearance: a firm with clean history and complete data is screened faster, while a firm with prior violations draws scrutiny on every line.

PREDICT scores the importer and the manufacturer, not just the product. A firm’s import history is an asset or a liability that compounds over time, every clean entry strengthens the risk profile that determines how quickly future shipments clear.

The Three Entry Outcomes: May Proceed, Detention, and Refusal

Every FDA entry line resolves into one of three dispositions. Understanding what each means, and what it does not mean, is essential to managing an import program.

May Proceed

A “May Proceed” message indicates that the product may proceed into U.S. commerce without FDA examination. It is important to read this disposition precisely: FDA explicitly states that “May Proceed” makes no determination that the product complies with all provisions of the Federal Food, Drug, and Cosmetic Act, and that it does not preclude later action if the article is subsequently found to be violative. A “May Proceed” is a release, not a certificate of compliance.

Detention

If FDA decides that a product appears to violate the law, it detains the product and issues a Notice of FDA Action, Detention to the importer, the owner, the consignee, and the customs broker. A detention is not a final refusal; it opens a window in which the importer may submit testimony, analytical results, or documentation to demonstrate that the product is in fact admissible, or may petition to recondition the product where reconditioning is permitted.

Refusal

If the importer cannot overcome the detention, FDA issues a Notice of Refusal of Admission. Refused product must be exported or destroyed under government supervision, generally within 90 days. For most refused articles this process is directed by CBP, but drugs subject to administrative destruction are destroyed by FDA rather than CBP. A refusal is a total loss of the shipment’s value plus the cost of destruction or re-export.

Import Alerts and Detention Without Physical Examination

The most serious and persistent admissibility mechanism is the Import Alert. After identifying a violation, FDA may place a firm, a product, or a manufacturer on an Import Alert and then detain future shipments without testing or physically examining them, a status FDA calls Detention Without Physical Examination (DWPE). Under DWPE, the burden shifts entirely to the importer: each shipment is presumptively detained, and the importer must affirmatively demonstrate admissibility, typically through private laboratory analysis meeting FDA’s specified methods, before the product can be released.

As of 2025, FDA maintained more than 230 active import alerts covering thousands of firms across more than 100 countries. Several pharmaceutical-relevant alerts have seen recent activity: Import Alert 66-41, covering unapproved new drugs, was revised in May 2026, and Import Alert 66-80 governing certain GLP-1 active pharmaceutical ingredients was substantially revised in 2026 in support of a CDER Office of Manufacturing Quality action. Removal from an Import Alert (“delisting”) requires the firm to petition FDA with evidence, frequently five consecutive compliant entries and documented corrective action, and the process can take many months during which every shipment is detained on arrival.

Placement on an Import Alert can convert a supply lane from routine to commercially unviable overnight. Because DWPE shifts the burden of proof to the importer for every subsequent shipment, the cost of a single sustained violation is measured not in one detention but in months of held inventory.

Prior Notice: What It Covers and What It Does Not

Importers frequently conflate Prior Notice with the drug entry process. They are distinct. Prior Notice, codified at 21 CFR Part 1 Subpart I (Sections 1.276 through 1.285) and rooted in the Public Health Security and Bioterrorism Preparedness and Response Act, applies to food for humans and animals, a category that includes dietary supplements and animal feed, and requires that FDA receive advance notice before the article arrives. The confirmed notice must reach FDA at least eight hours before arrival by ocean, four hours by air or rail, and two hours by road. A September 2025 final rule, effective October 1, 2026, additionally requires that Prior Notice for food arriving by international mail include the mail service name and a tracking number.

For finished pharmaceuticals and most biologics, Prior Notice in this statutory sense does not apply, but the distinction must be drawn carefully, because a firm importing a mixed portfolio (for example, a nutraceutical or medical food alongside drug products) may have Prior Notice obligations for part of its inventory and not others. The safe practice is to classify each article correctly and confirm its specific entry requirements rather than assume a single workflow applies across a portfolio.

Prior Notice is a food and animal-feed requirement, not a universal drug-import step. Misclassifying an article, treating a medical food as a drug, or vice versa, creates admissibility exposure regardless of how well the rest of the entry is prepared.

Building an Audit-Ready Import Program

The throughline of the FDA import framework is that admissibility is earned before arrival and sustained over time. A defensible import program rests on a small number of disciplines: verifying that every foreign establishment in the supply chain is registered under Part 207 and that products are listed; maintaining an active, physically present U.S. agent; ensuring entry filings carry complete and accurate Affirmation of Compliance codes and valid Drug Registration Numbers; reconciling the firm’s import history to protect its PREDICT risk profile; and maintaining the chain-of-custody and condition documentation that supports admissibility if a shipment is detained. Each of these is controllable. None of them depends on the product itself, they depend on the systems and records around it.

For regulated importers, the most expensive failures are documentary and historical, not physical. An import program that treats entry data, registration status, and compliance history as quality-controlled processes, rather than clerical afterthoughts, is one that clears faster and absorbs fewer losses.

How Euro-American Worldwide Logistics Supports Pharmaceutical Import Compliance

Euro-American Worldwide Logistics operates a licensed in-house U.S. Customs Brokerage integrated with GMP-compliant, ISO 9001-certified warehousing and validated cold chain storage at its 40,000-square-foot Worcester, Massachusetts facility, 40 miles west of Boston. For pharmaceutical and biologics importers, this integration means the entity filing the FDA entry is the same entity holding the product under validated, audit-ready conditions, eliminating the handoff gaps where admissibility documentation is most often lost.

Euro-American’s import compliance support includes:

• Licensed U.S. Customs Brokerage with FDA entry filing through ACE, including correct Affirmation of Compliance coding and Drug Registration Number submission to maximize the probability of an automated release
• Verification of foreign establishment registration and drug listing status under 21 CFR Part 207 before product is shipped
• Coordination of entry bonds and pre-arrival entry preparation to align with PREDICT screening and ImportShield review timelines
• Validated GMP storage across ULT (-80°C), frozen (-20°C), refrigerated (2-8°C), and controlled-room-temperature (15-25°C) ranges for product held pending admissibility determination
• ALCOA+-compliant chain-of-custody and condition documentation to support the importer’s response in the event of a detention
• Prior Notice filing for food, dietary supplement, and animal-feed articles where applicable, with correct article classification across mixed portfolios

The result is a single accountable partner across customs entry, FDA admissibility, and GMP storage, the three functions that determine whether regulated product clears the border and remains compliant once it does.

Conclusion

FDA admissibility for pharmaceutical and biologics imports is decided by a chain of obligations that begins long before a shipment reaches the port: foreign establishment registration, an active U.S. agent, accurate electronic entry data, a defensible compliance history, and correct article classification. The product inside the container matters, but it is rarely the variable that determines whether an entry clears. The variables that do, registration status, entry data quality, and import history, are precisely the ones a disciplined import program can control. Importers who treat these as quality processes clear faster, draw less scrutiny, and avoid the detentions and refusals that turn a routine supply lane into a recurring loss.

If your organization imports pharmaceuticals, biologics, or APIs and wants to strengthen FDA admissibility while keeping product under validated GMP conditions, contact Euro-American Worldwide Logistics today.